Biotech Unusual Volume: Evogene (NYSE:EVGN), Heat Biologics Inc (NASDAQ:HTBX), Alseres Pharmaceuticals (OTCMKTS:ALSE), EntreMed (NASDAQ:ENMD)

Evogene Ltd. (NYSE:EVGN)(TASE:EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, announced today its financial results for the fourth quarter and year ended December 31, 2013. Evogene Ltd (NYSE:EVGN) stock performance was 2.35% in last session and finished the day at $19.56. Traded volume was 54,493 million shares in the last session and the average volume of the stock remained 8.87 million shares.

Heat Biologics Inc (NASDAQ:HTBX)soared by more than 9% on Wednesday after it reported to have submitted a revised protocol to the FDA in relation to its Phase II trial of HS-110 drug. The company’s HS-110 drug is aimed at treating non-small cell cancer. Heat Biologics Inc (NASDAQ:HTBX) rose 8.48 percent to $7.42 yesterday on volume of 64,085.00 million shares. The intra-day range of the stock was $6.84 to $8.00. Heat Biologics Inc (NASDAQ:HTBX) has a market capitalization of $47.23 million.

Alseres Pharmaceuticals, Inc. (OTCMKTS:ALSE) is a development-stage company. The Company is a biotechnology company focused on the development of diagnostic and therapeutic products primarily for disorders in the central nervous system, or CNS. Alseres Pharmaceuticals, Inc. (OTCMKTS:ALSE)’s stock on Mar20, 2014 reported a decrease of -27.27% to the closing price of $0.0400. Its fifty two weeks range is $0.02 -$0.15. The total market capitalization recorded $1.23 million. The overall volume in the last trading session was 73,088 million shares. In its share capital, Alseres Pharmaceuticals, Inc. (OTCMKTS:ALSE) has 23.06 million outstanding shares.

EntreMed, Inc (NASDAQ:ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of diseases, announced that it has moved to expand its Phase 2 clinical trial for its drug candidate ENMD-2076 in advanced ovarian clear cell carcinoma (OCCC) with the submission of a new drug global clinical trial application with China’s Food and Drug Administration (CFDA). On Thursday, shares of EntreMed Inc (NASDAQ:ENMD) advanced 12.64% to close the day at $2.05. Company return on investment (ROI) is -54.20% and its monthly performance is recorded as 10.81%. EntreMed Inc (NASDAQ:ENMD) quarterly revenue growth is 32.26%.